CL2018000249A1 - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
CL2018000249A1
CL2018000249A1 CL2018000249A CL2018000249A CL2018000249A1 CL 2018000249 A1 CL2018000249 A1 CL 2018000249A1 CL 2018000249 A CL2018000249 A CL 2018000249A CL 2018000249 A CL2018000249 A CL 2018000249A CL 2018000249 A1 CL2018000249 A1 CL 2018000249A1
Authority
CL
Chile
Prior art keywords
idh1
isocitrate dehydrogenase
dehydrogenase inhibitor
mutated isocitrate
aduct
Prior art date
Application number
CL2018000249A
Other languages
English (en)
Inventor
Heiko Schirmer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2018000249A1 publication Critical patent/CL2018000249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE AL ÁCIDO ADUCTIVO (2E)-BUT-2-ENEDIOICO Y ÁCIDO 3-(2-{[4- (TRIFLUOROMETOXI)FENIL]AMINO}-1-[(1R,5R)-3,3,5-TRIMETILCICLOHEXIL]-1H-BENZIMIDAZOL-5- IL)PROPANOICO (1:4), A MÉTODOS PARA PREPARAR ESTE ADUCTO, COMPOSICIONES QUE COMPRENDEN ESTE ADUCTO Y, TAMBIÉN AL USO DE ESTE ADUCTO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UNA ENFERMEDAD.</p>
CL2018000249A 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h CL2018000249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27

Publications (1)

Publication Number Publication Date
CL2018000249A1 true CL2018000249A1 (es) 2018-07-06

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000249A CL2018000249A1 (es) 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031655B1 (ru) 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
US10137110B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
CA2988356A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824952B2 (ja) 2015-07-07 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
EP3661559A1 (en) 2017-08-01 2020-06-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Combination of midh1 inhibitors and dna hypomethylating agents (hma)
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
EP4186525A4 (en) 2020-07-21 2024-04-03 Daiichi Sankyo Co Ltd COMBINATION DRUG OF TEMOZOLOMIDE AND MUTATED IDH1 ENZYME INHIBITOR

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2445345B1 (en) * 2009-06-23 2014-08-27 The Translational Genomics Research Institute Benzamide derivatives
JP5808818B2 (ja) * 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
KR20140069235A (ko) * 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
WO2015121209A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
EA031655B1 (ru) * 2014-02-11 2019-02-28 Байер Фарма Акциенгезельшафт Бензимидазол-2-амины в качестве ингибиторов midhi
US10137110B2 (en) * 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors
CN107108522B (zh) * 2014-10-23 2020-12-01 德国癌症研究中心 作为mIDH1抑制剂的苯并咪唑-2-胺
CA2988356A1 (en) * 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
JP6824952B2 (ja) 2015-07-07 2021-02-03 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール
CN108026052B (zh) 2015-07-16 2021-10-08 德国癌症研究公共权益基金会 作为mIDH1抑制剂的5-羟烷基苯并咪唑类
EP3121166A1 (en) * 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
CN107810181B (zh) 2021-06-22
JP2018521095A (ja) 2018-08-02
CR20180053A (es) 2018-03-20
NI201800014A (es) 2018-09-06
TW201708193A (zh) 2017-03-01
US10344004B2 (en) 2019-07-09
ES2860693T3 (es) 2021-10-05
MX2018001205A (es) 2018-04-24
CU20180014A7 (es) 2018-06-05
WO2017016992A1 (en) 2017-02-02
AU2016300980B2 (en) 2020-12-24
EP3328837B1 (en) 2021-01-06
EP3328837A1 (en) 2018-06-06
CA2993473A1 (en) 2017-02-02
ECSP18006465A (es) 2018-04-30
CN107810181A (zh) 2018-03-16
BR112018001534A2 (pt) 2018-09-11
SV2018005621A (es) 2018-12-05
CO2018000793A2 (es) 2018-05-10
US20180222870A1 (en) 2018-08-09
HK1252449A1 (zh) 2019-05-24
AU2016300980A1 (en) 2017-12-21
TN2018000038A1 (en) 2019-07-08
DOP2018000027A (es) 2018-02-28
IL256024A (en) 2018-01-31
EA201890386A1 (ru) 2018-08-31
AR105493A1 (es) 2017-10-11
JP6804516B2 (ja) 2020-12-23
PE20181038A1 (es) 2018-07-03
KR20180030789A (ko) 2018-03-26

Similar Documents

Publication Publication Date Title
CL2018000249A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
PE20170665A1 (es) Anticuerpos anti-tau humanizados
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
EA201692437A1 (ru) Комбинация
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
GT201400111A (es) Triazolopiridinas sustituidas
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2017002610A (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
SG11201805123XA (en) Pharmaceutical composition comprising anti-human tslp receptor antibody
CL2016000027A1 (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán.
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
EA201591899A1 (ru) Введение nsaid и соответствующие композиции, способы и системы